DECA is a privately held product development organization dedicated to the creation of innovative healthcare technologies designed for seamless integration into our global sales network. Our technologies are formulated by board certified pharmacologists and undergo rigorous safety, tolerability and efficacy testing and are then proven IRB reviewed human clinical trials. Once safety and efficacy are confirmed the technology is professionally positioned to maximize valuation by strategic introduction into our global commercialization network. DECA has developed numerous platform technologies that have become cornerstone products for some highly successful companies including Richwood Pharmaceuticals (Merged with Shire Pharmaceuticals in 1997), Integrity Pharmaceuticals, Xanodyne Pharmaceuticals and the Union Springs Family of Companies (Acquired by Enzymotec LTD NASDAQ ENZY 2017).